Lonza to manufacture Sunshine Biopharma's anti-cancer compound
Adva-27a is Sunshine Biopharma's lead anticancer compound, a Topoisomerase II inhibitor, small molecule that has recently been shown to be effective against many cancers
Sunshine Biopharma Inc, the Canadian pharmaceutical company focused on the research, development and commercialisation of drugs for the treatment of various forms of cancer, has entered into an agreement with Swiss firm Lonza for manufacturing its anti-cancer drug, Adva-27a.
“Lonza’s expertise and experience in small molecule development and manufacturing of active pharmaceutical ingredients (APIs), was an ideal fit for Sunshine’s Adva-27a. Lonza’s manufacturing capacity ranges from gram quantities for process validation to kilogram amounts for clinical trials and ton quantities for commercialisation,” said Sunshine Biopharma in a press release. Manufacturing will begin at Lonza’s Nansha, China facility with the remaining key steps to be conducted in Lonza’s high containment cytotoxic facility in Visp, Switzerland.
“We are delighted to have a global leader like Lonza as our manufacturing partner. We have made significant recent strides in terms of research results showing the effectiveness of our lead compound against cancer cells as well as in our manufacturing and recent fund raising efforts,” said Dr Steve Slilaty, President and CEO, of Sunshine Biopharma.
James Leresche, Head of Lonza’s Chemical Development Services, added, “We are very excited to be working with Sunshine Biopharma on the development of their promising anti-cancer compound. This development project is an example of Lonza’s support and commitment to emerging companies with innovative and potentially life-saving treatments like Adva-27a.”
“Lonza’s expertise and experience in small molecule development and manufacturing of active pharmaceutical ingredients (APIs), was an ideal fit for Sunshine’s Adva-27a. Lonza’s manufacturing capacity ranges from gram quantities for process validation to kilogram amounts for clinical trials and ton quantities for commercialisation,” said Sunshine Biopharma in a press release. Manufacturing will begin at Lonza’s Nansha, China facility with the remaining key steps to be conducted in Lonza’s high containment cytotoxic facility in Visp, Switzerland.
“We are delighted to have a global leader like Lonza as our manufacturing partner. We have made significant recent strides in terms of research results showing the effectiveness of our lead compound against cancer cells as well as in our manufacturing and recent fund raising efforts,” said Dr Steve Slilaty, President and CEO, of Sunshine Biopharma.
James Leresche, Head of Lonza’s Chemical Development Services, added, “We are very excited to be working with Sunshine Biopharma on the development of their promising anti-cancer compound. This development project is an example of Lonza’s support and commitment to emerging companies with innovative and potentially life-saving treatments like Adva-27a.”